• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Bausch + Lomb Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    4/30/25 7:02:13 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care
    Get the next $BLCO alert in real time by email
    blco-20250430
    0001860742FALSEBausch & Lomb Corp00018607422025-04-302025-04-30

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 8-K
    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934
    April 30, 2025
    Date of Report (Date of the earliest event reported)
    Bausch + Lomb Corporation
    (Exact Name of Registrant as Specified in Its Charter)
    Canada
    001-41380
    98-1613662
    (State or Other Jurisdiction of
    Incorporation or Organization)
    (Commission
    File Number)
    (I.R.S. Employer
    Identification Number)
    520 Applewood Crescent
    Vaughan, Ontario
    Canada L4K 4B4
    (Address of Principal Executive Offices)(Zip Code)
    (905) 695-7700
    (Registrant’s telephone number, including area code)
    N/A
    (Former name or former address, if changed since last report)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    ☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each class
    Trading Symbol(s)
    Name of each exchange on which registered
    Common Shares, No Par Value
    BLCO
    New York Stock Exchange
    Toronto Stock Exchange
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 2.02 Results of Operations and Financial Condition.
    On April 30, 2025, Bausch + Lomb Corporation (the “Company”) issued a press release announcing results of operations for the quarter ended March 31, 2025 and certain other financial information as of and for the quarter ended March 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by this reference.
    The information in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.
    Item 9.01. Financial Statements and Exhibits.
    (d)    Exhibits
    Exhibit No.Description
    99.1*
    Press Release of Bausch + Lomb Corporation, respecting financial results for the first quarter of 2025, dated April 30, 2025
    104*Cover Page Interactive Data File (formatted as Inline XBRL)
    ____________________________________
    * Filed herewith.



    Signatures

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    BAUSCH + LOMB CORPORATION
    By:
    /s/ Sam Eldessouky
    Name:Sam Eldessouky
    Title:Executive Vice President, Chief Financial Officer
    Date: April 30, 2025

    Get the next $BLCO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BLCO

    DatePrice TargetRatingAnalyst
    5/2/2025$20.00 → $15.00Buy
    H.C. Wainwright
    3/28/2025$24.00 → $15.00Overweight → Equal Weight
    Wells Fargo
    12/11/2024$24.00 → $22.00Buy → Neutral
    Citigroup
    12/2/2024$19.00Overweight → Equal-Weight
    Morgan Stanley
    10/15/2024$19.00 → $25.00In-line → Outperform
    Evercore ISI
    7/10/2024$19.00Outperform
    Raymond James
    5/6/2024$16.00 → $18.00Equal-Weight → Overweight
    Morgan Stanley
    1/4/2024$19.00 → $17.00Outperform → In-line
    Evercore ISI
    More analyst ratings

    $BLCO
    SEC Filings

    See more
    • Bausch + Lomb Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

      8-K - Bausch & Lomb Corp (0001860742) (Filer)

      6/27/25 7:33:08 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Bausch & Lomb Corp (0001860742) (Filer)

      6/18/25 4:52:57 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Bausch & Lomb Corp (0001860742) (Filer)

      6/10/25 9:05:43 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care

    $BLCO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and Chairman of the Board Saunders Brent L bought $248,072 worth of shares (22,000 units at $11.28) and was granted 22,000 shares, increasing direct ownership by 6% to 741,156 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      5/27/25 8:16:24 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Director Von Eschenbach Andrew C. bought $19,925 worth of shares (1,695 units at $11.76), increasing direct ownership by 4% to 41,748 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      5/6/25 4:30:10 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • CEO and Chairman of the Board Saunders Brent L bought $505,067 worth of shares (32,250 units at $15.66) and was granted 32,250 shares, increasing direct ownership by 11% to 627,419 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      8/7/24 5:29:48 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care

    $BLCO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President, Surgical Bonnefoy Luc covered exercise/tax liability with 968 shares, decreasing direct ownership by 1% to 73,383 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      6/16/25 4:46:45 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Director Von Eschenbach Andrew C. was granted 20,338 shares, increasing direct ownership by 49% to 62,086 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      5/28/25 4:11:49 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Director Ross Thomas W. Sr. was granted 20,338 shares, increasing direct ownership by 51% to 60,391 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      5/28/25 4:10:50 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care

    $BLCO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright reiterated coverage on Bausch + Lomb with a new price target

      H.C. Wainwright reiterated coverage of Bausch + Lomb with a rating of Buy and set a new price target of $15.00 from $20.00 previously

      5/2/25 7:51:06 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Bausch + Lomb from Overweight to Equal Weight and set a new price target of $15.00 from $24.00 previously

      3/28/25 8:14:16 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb downgraded by Citigroup with a new price target

      Citigroup downgraded Bausch + Lomb from Buy to Neutral and set a new price target of $22.00 from $24.00 previously

      12/11/24 7:25:38 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care

    $BLCO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bausch + Lomb Will Release Second-Quarter 2025 Financial Results on July 30 and Hold Investor Day on Nov. 13

      Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter financial results on Wednesday, July 30, 2025. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Bausch + Lomb will hold an investor day on Thursday, Nov. 13, 2025, where the company will provide a business update and highlight its innovative product pipeline. Additional details will follow closer to the event. Second-Qua

      6/30/25 6:58:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Announces Closing of Upsized €675 Million Senior Secured Notes Offering and Partial Credit Agreement Refinancing, Including Upsized $2.325 Billion Term Loan Facility

      Bausch + Lomb Corporation (NYSE/TSX:BLCO) ("Bausch + Lomb" or the "company"), a leading global eye health company dedicated to helping people see better to live better, today announced that its subsidiaries, Bausch+Lomb Netherlands B.V. and Bausch & Lomb Incorporated (collectively, the "Issuers"), have closed the upsized offering of €675 million aggregate principal amount of senior secured floating rate notes due 2031 (the "Notes"). In addition, the company announced that it has completed a partial refinancing of its credit agreement, and in connection with such refinancing, it has entered into a third amendment (the "Third Amendment") to its existing credit agreement providing for a $2.325

      6/26/25 4:30:00 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Announces Pricing of Upsized Senior Secured Notes Offering

      Bausch + Lomb Corporation (NYSE/TSX:BLCO) ("Bausch + Lomb" or the "company"), a leading global eye health company dedicated to helping people see better to live better, today announced that its subsidiaries, Bausch+Lomb Netherlands B.V. and Bausch & Lomb Incorporated (collectively, the "Issuers"), have priced the offering of €675 million aggregate principal amount of senior secured floating rate notes due 2031 ("Notes"). The size of the offering was increased from the previously announced €600 million aggregate principal amount of Notes. The Notes will be sold to investors at a price of 99.500% of the principal amount thereof. As previously announced, the company is also seeking to partia

      6/18/25 4:30:00 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care

    $BLCO
    Financials

    Live finance-specific insights

    See more
    • Bausch + Lomb Will Release Second-Quarter 2025 Financial Results on July 30 and Hold Investor Day on Nov. 13

      Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter financial results on Wednesday, July 30, 2025. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Bausch + Lomb will hold an investor day on Thursday, Nov. 13, 2025, where the company will provide a business update and highlight its innovative product pipeline. Additional details will follow closer to the event. Second-Qua

      6/30/25 6:58:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Announces First-Quarter 2025 Results

      Revenue of $1.137 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $212 Million Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $126 Million Revenue Grew 3% as Reported and 5% on a Constant Currency1 Basis Compared to the First Quarter of 2024 Updating Full-Year 2025 Guidance to Reflect Estimated One-Time Impact of enVista® Intraocular Lenses Voluntary Recall and Impact of Foreign Exchange Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2025 financial results. "Our core business is performing well, and we remain focused on positioning

      4/30/25 6:57:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Will Release First-Quarter 2025 Financial Results on April 30

      Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter financial results on Wednesday, April 30, 2025. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date:     Wednesday, April 30, 2025   Time:     8 a.m. ET   Webcast:     https://www.webcaster4.com/Webcast/Page/2883/51713   Participant Event Dial-in:     +

      3/26/25 7:45:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care

    $BLCO
    Leadership Updates

    Live Leadership Updates

    See more
    • Bausch + Lomb Announces 2025 Annual Meeting of Shareholders Results

      Bausch + Lomb Corporation (NYSE/TSX:BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2025 Annual Meeting of Shareholders (the "Annual Meeting") held on May 21, 2025. Detailed results of the vote follow: Name For   Against   Broker Non-Votes Nathalie Bernier   337,617,248   1,924,336   8,383,437 Gary Hu   337,591,706   1,949,878   8,383,437 Brett Icahn   337,474,287   2,067,297   8,383,437 Sarah B. Kavanagh   337,602,211   1,939,373  

      5/21/25 4:30:00 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Announces Appointment of Karen L. Ling to Board of Directors

      Richard De Schutter to Retire from Board Following 2024 Annual Meeting Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Karen L. Ling has been appointed to its Board of Directors (the "Board"), effective immediately. Current director Richard De Schutter will retire from the Board effective as of the company's 2024 Annual Meeting of Shareholders (the "Annual Meeting"). With Ms. Ling's appointment, the Board has been temporarily expanded to 11 members and is expected to revert to 10 directors following the Annual Meeting. "Since my return to the company, Richard has been a trusted advisor,

      2/28/24 8:00:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO

      Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying down the company's debt GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced that its Board of Directors has appointed Joseph C. Papa as president and CEO, effective February 21, 2024. Mr. Papa succeeds Haywood Miller, who will step down from his role as interim CEO, effective February 21, 2024. "Following a thorough search process, we are pleased to appoint Joe Papa as president and CEO of Emergent," sai

      2/21/24 7:00:00 AM ET
      $BLCO
      $EBS
      Ophthalmic Goods
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $BLCO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Bausch + Lomb Corporation

      SC 13G - Bausch & Lomb Corp (0001860742) (Subject)

      2/14/23 5:14:30 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care